NextFin News - GE HealthCare Technologies shares tumbled on Wednesday after the medical technology giant lowered its full-year profit forecast, citing a volatile cocktail of rising costs and geopolitical friction. The company reported first-quarter revenue of $5.13 billion, a 7% increase from the previous year, but the top-line growth was overshadowed by a significant contraction in net income, which fell to $389 million from $564 million in the same period last year.
The Chicago-based firm now expects adjusted earnings per share for 2026 to fall between $4.80 and $5.00, a downward revision from its previous guidance of $4.95 to $5.15. This adjustment reflects the mounting pressure of tariffs and supply chain disruptions linked to ongoing global conflicts. Chief Executive Officer Peter Arduini noted during the earnings call that bilateral tariffs between the U.S. and China alone account for roughly 75% of the total net impact on the company’s bottom line, highlighting the vulnerability of specialized medical manufacturing to trade policy shifts under U.S. President Trump.
Operating income for the quarter dropped to $515 million from $629 million, squeezed by restructuring charges and the costs associated with the recent acquisition of Intelerad. While the company’s Pharmaceutical Diagnostics business showed continued momentum, the broader Imaging and Ultrasound segments faced headwinds from higher input costs. Arduini characterized the start of the year as a period of "strong execution" in the U.S. market, yet acknowledged that the "turbulent tariff backdrop" required a more cautious outlook for the remainder of the fiscal year.
Market reaction was swift, with the stock falling as much as 12% in early trading before paring some losses. The decline reflects investor anxiety over margin sustainability in an environment where "self-help cost management," as described by Chief Financial Officer James Saccaro, may not be enough to offset macro-level shocks. Saccaro emphasized that the company is aggressively working to reduce tariff exposure, but the immediate financial weight of these duties remains a primary drag on earnings.
The cautious stance on China is particularly telling. GE HealthCare expects a decline in business within the region this year, a pivot from previous growth expectations. This "prudent approach" is a direct response to the shifting trade landscape, where medical devices have become a focal point of protectionist measures. While some analysts suggest that the company’s robust order backlog provides a safety net, the downward revision suggests that the conversion of that backlog into profitable revenue is becoming increasingly expensive.
Despite the guidance cut, the company maintained its organic revenue growth forecast of 4% to 6%. This suggests that demand for high-end medical imaging and diagnostic tools remains resilient, even if the cost of delivering those tools is rising. The divergence between steady demand and shrinking margins underscores the central challenge for GE HealthCare: navigating a world where the efficiency of global supply chains is being sacrificed for geopolitical alignment.
Explore more exclusive insights at nextfin.ai.
